Phase 1 study in healthy participants of the safety, pharmacokinetics, and pharmacodynamics of enpatoran (M5049), a dual antagonist of toll‐like receptors 7 and 8

• Váldodahkkit: Andreas Port (Dahkki), Jamie V. Shaw (Dahkki), Lena Klopp‐Schulze (Dahkki), Afrim Bytyqi (Dahkki), Claudia Vetter (Dahkki), Elizabeth Hussey (Dahkki), Nadra Mammasse (Dahkki), Victor Ona (Dahkki), Angelika Bachmann (Dahkki), Denis Strugala (Dahkki), Christian Reh (Dahkki), Kosalaram Goteti (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Wiley, 2021-10-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Abstract This study evaluated the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple oral doses of enpatoran (formerly named M5049), a new toll‐like receptor (TLR) 7 and 8 dual antagonist, and the effect of food on a single dose in healthy participants. In...